Literature DB >> 18385728

The cancer biomarker problem.

Charles L Sawyers1.   

Abstract

Genomic technologies offer the promise of a comprehensive understanding of cancer. These technologies are being used to characterize tumours at the molecular level, and several clinical successes have shown that such information can guide the design of drugs targeted to a relevant molecule. One of the main barriers to further progress is identifying the biological indicators, or biomarkers, of cancer that predict who will benefit from a particular targeted therapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18385728     DOI： 10.1038/nature06913

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


  270 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Elevated serum annexin A1 as potential diagnostic marker for lung cancer: a retrospective case-control study.

Authors:  Biaoxue Rong; Chongchong Zhao; Hua Liu; Zongjuan Ming; Xiguang Cai; Wenlong Gao; Shuanying Yang
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

3.  A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth.

Authors:  David Y Chen; Yishan Lee; Brian A Van Tine; Adam C Searleman; Todd D Westergard; Han Liu; Ho-Chou Tu; Shugaku Takeda; Yiyu Dong; David R Piwnica-Worms; Kyoung J Oh; Stanley J Korsmeyer; Ann Hermone; Richard Gussio; Robert H Shoemaker; Emily H-Y Cheng; James J-D Hsieh
Journal:  Cancer Res       Date:  2011-12-13       Impact factor: 12.701

Review 4.  Quantifying factors for the success of stratified medicine.

Authors:  Mark R Trusheim; Breon Burgess; Sean Xinghua Hu; Theresa Long; Steven D Averbuch; Aiden A Flynn; Alfons Lieftucht; Abhijit Mazumder; Judy Milloy; Peter M Shaw; David Swank; Jian Wang; Ernst R Berndt; Federico Goodsaid; Michael C Palmer
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

Review 5.  Clinical metabolomics paves the way towards future healthcare strategies.

Authors:  Sebastiano Collino; François-Pierre J Martin; Serge Rezzi
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

Review 6.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

Review 7.  Challenges and standards in reporting diagnostic and prognostic biomarker studies.

Authors:  Francisco Azuaje; Yvan Devaux; Daniel Wagner
Journal:  Clin Transl Sci       Date:  2009-04       Impact factor: 4.689

8.  Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer.

Authors:  Kristin A Spivey; Jacqueline Banyard; Luisa M Solis; Ignacio I Wistuba; Justine A Barletta; Leena Gandhi; Henry A Feldman; Scott J Rodig; Lucian R Chirieac; Bruce R Zetter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05       Impact factor: 4.254

Review 9.  Envisioning the future of early anticancer drug development.

Authors:  Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

10.  Skeletal Muscle Metrics on Clinical 18F-FDG PET/CT Predict Health Outcomes in Patients with Sarcoma.

Authors:  Brent Foster; Robert D Boutin; Leon Lenchik; David Gedeon; Yu Liu; Vinay Nittur; Ramsey D Badawi; Chin-Shang Li; Robert J Canter; Abhijit J Chaudhari
Journal:  J Nat Sci       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.